Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV: Interact with HCV Experts on Patient Cases
Gastroenterology
Curriculum:
Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV
Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
March 15, 2016
March 15, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.
Relevant Terms:
HCV; drug-drug interactions; interferon-free regimens; HIV/HCV coinfection
Andrew J. Muir, MD, MHS, FACP
Andrew Muir, MD, MHS, FACP
Chief, Division of Gastroenterology
Director GI/Hepatology Research Group
Associate Professor of Medicine
Duke University Department of Medicine
Durham, NC
Bio
Andrew J. Muir, MD, MHS, FACP, received his medical and master of health sciences degree from Duke University in Durham, North Carolina. He completed his residency in the department of medicine, where he served as chief resident. Dr. Muir also completed fellowships in gastroenterology and health services research at Duke and at the Durham Veterans Administration Medical Center, respectively. He joined the faculty of Duke in the division of gastroenterology.Dr. Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases, including hepatitis C infection, hepatocellular carcinoma, and African-American patient response to hepatitis therapies, as well as racial disparities and issues affecting access to care in hepatitis C treatment and liver transplantation.
Dr. Muir helped to create and now leads the site-based research program in gastroenterology at the Duke Clinical Research Institute. He has led successful global clinical trials, including new therapeutic approaches in patients with hepatitis C infection. Dr. Muir has a long-standing commitment to improving racial and socioeconomic disparities in health care, as evidenced by his work on health inequalities as a senior research fellow at the Duke Center for Health Policy. Dr. Muir has received the Golden Apple Teaching Award, the Eugene A. Stead, Jr. Teaching Award, and the Joseph Greenfield, Jr., MD Mentor Award.
Dr. Muir has authored or co-authored more than 50 peer-reviewed publications in journals such as Nature, New England Journal of Medicine, Annals of Internal Medicine, Hepatology, and Gastroenterology. These include reports evaluating genomics-based strategies for predicting therapeutic response in patients with hepatitis C.
Nancy Reau, MD, FAASLD, AGAF
Nancy Reau, MD, FAASLD, AGAF
Associate Professor of Medicine
Section Chief, Hepatology
Associate Director of Solid Organ Transplantation
Rush University Medical Center
Chicago, IL
Bio
Nancy Reau, MD, is associate professor of medicine at the University of Chicago School of Medicine. She received her Bachelor of Science degree from Oberlin College in Oberlin, OH, and her medical degree from Ohio State University College of Medicine in Columbus. She completed her internship, residency, and a fellowship in gastroenterology/hepatology at Ohio State and a fellowship in advanced transplant hepatology at Johns Hopkins Hospital in Baltimore, MD. Dr. Reau is board certified in internal medicine, gastroenterology, and transplant hepatology.Dr. Reau is an academic hepatologist and an expert in hepatitis B and C, liver transplantation, and nonalcoholic liver disease. She is the current chairwoman of the American Association for the Study of Liver Diseases Public and Clinical Policy Committee. She has presented numerous invited lectures focused on fatty liver disease, viral hepatitis, cirrhosis, and liver transplantation. Her research interests focus on viral hepatitis, liver transplantation, and complications of chronic liver disease.
Mark Sulkowski, MD
Mark Sulkowski, MD
Professor of Medicine
Medical Director of the Viral Hepatitis Center
Johns Hopkins School of Medicine
Baltimore, MD
Bio
Mark S. Sulkowski, MD, is professor of medicine and the medical director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology / Hepatology at the Johns Hopkins University School of Medicine in Baltimore, MD. He received his medical degree from Temple University School of Medicine in Philadelphia, PA, and completed his fellowship in infectious diseases at Johns Hopkins.
Dr. Sulkowski has been the lead principal investigator for numerous clinical trials related to the management of viral hepatitis, including those studying novel agents. He is a member of the Hepatitis Transformative Sciences Group of the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group. Dr. Sulkowski is also a member of numerous professional societies, including the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Infectious Diseases Society of America. He is an elected member for the American Society for Clinical Investigation.
Dr. Sulkowski is widely published with works in Annals Internal Medicine, Nature, New England Journal of Medicine, The Journal of the American Medical Association, Journal of Infectious Diseases, Journal of Hepatology, Gastroenterology, and Hepatology. As an invited lecturer, he has presented discussions of the management of viral hepatitis around the world at major national and international medical meetings.
| 1. | Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations in mild as well as severe disease. | 2. | Apply the clinical evidence to optimize treatment duration, monitoring strategies, and drug-drug interactions for newly approved and emerging interferon-free regimens. |
| 3. | Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal impairment, and HCV genotype 3. |
| 1. | Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations in mild as well as severe disease. |
| 2. | Apply the clinical evidence to optimize treatment duration, monitoring strategies, and drug-drug interactions for newly approved and emerging interferon-free regimens. |
| 3. | Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal impairment, and HCV genotype 3. |
Provided by Vindico Medical Education 
Release Date: March 15, 2016
Expiration Date: March 15, 2017
Physician Continuing Medical Education
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Type of Activity
Knowledge and Performance
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Type of Activity
Knowledge and Performance
Target Audience
The intended audience for this activity is gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.
Educational Support
This activity is supported by an educational grant from Gilead Sciences Medical Affairs.
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Faculty
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Andrew J. Muir, MD, MHS has received Consulting Fees: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Theravance.
Contracted Research: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Roche, Theravance.
Nancy Reau, MD, FAASLD, AGAF has received Consulting Fees: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Salix.
Contracted Research: AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
Mark Sulkowski, MD has received Consulting Fees: AbbVie, Achillion, Gilead, Janssen, Merck.
Contracted Research (paid directly to institution): AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck.
External Reviewers
Joseph K. Lim, MD has received Consulting Fees: Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Hologic, Janssen.
Ronald A. Codario, MD, FACP, FNLA, CCMEP has no relevant financial relationship to disclose.
Planners
Vindico Medical Education Staff: No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Vindico Medical Education Staff: No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Media
Internet
Disclaimer
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Internet
Disclaimer
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Method of Participation and Request for Credit
To participate in this CME activity, you must complete the activity in its entirety and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
